Research

The 11th annual Appel Alzheimer's Disease Research Institute Symposium brought together leading scientists and clinicians in the field to present the latest advances in understanding Alzheimer’s and related neurodegenerative diseases. 

Awards, honors and achievements for the month of November.  

The Dean’s Symposium  on Innovation and Entrepreneurship, which took place Nov. 7, celebrated innovation and Weill Cornell Medicine’s entrepreneurial spirit.

Located one block from Weill Cornell Medicine’s main campus on Manhattan’s Upper East Side, the site will add approximately 200,000 square feet of dedicated research space. 

Researchers at Weill Cornell Medicine, Cornell Tech and Cornell's Ithaca campus have demonstrated the use of AI-selected natural images and AI-generated synthetic images as neuroscientific tools for probing the visual processing areas of the brain.

Dr. Bishoy M. Faltas, the Gellert Family-John P. Leonard, M.D. Research Scholar and an assistant professor of medicine at Weill Cornell Medicine, has been awarded a $4 million, seven-year MERIT grant from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

Dr. Conor Liston, professor of psychiatry and of neuroscience in the Department of Psychiatry and the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine, received the 2023 Thomas William Salmon Medal in Psychiatry from The New York Academy of Medicine. 

A team led by researchers at Weill Cornell Medicine has used an AI-based approach to uncover underlying patterns among the conditions in which people are born, grow, live, work, and age, termed social determinants of health (SDoH), and then linked each pattern to children’s health outcomes.

Researchers from Weill Cornell Medicine provide the first national estimate of caregivers’ pain and arthritis experiences that can limit their ability to perform necessary tasks while caring for older family members.

Researchers at Weill Cornell Medicine found that partnering with local religious leaders boosted adoption of family planning methods in Tanzania.

A team at Weill Cornell Medicine has mapped the location and spatial features of blood-forming cells within human bone marrow.

In patients with severe artery blockage in the lower leg, an artery-supporting device called a resorbable scaffold is superior to angioplasty, which has been the standard treatment, according to the results of a large international clinical trial co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Co-led by Dr. David Artis at Weill Cornell Medicine, the Allen Discovery Center for Neuroimmune Interactions at the Icahn School of Medicine at Mount Sinai hopes to revolutionize the field of medicine with a groundbreaking project to understand how the human body senses health and disease.

Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta cells in a preclinical model of diabetes. The findings hold promise for future therapeutics that will improve the lives of individuals with type 2 diabetes—a condition that affects more than half a billion people worldwide.

Researchers at Weill Cornell Medicine have demonstrated how amyloid beta, a peptide associated with Alzheimer’s disease, can interact with a protein receptor on immune cells in the brain triggering a reaction that damages blood vessels and leads to neurodegeneration. 

A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in type 2 diabetes, according to a new study by Weill Cornell Medicine investigators.

A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed that the “radiopharmaceutical” was well tolerated and demonstrated promising antitumor activity.

Awards, honors and achievements for the month of October.  

Ambulance-based mobile stroke units (MSU) can reach patients faster to deliver clost-busting drugs that increase the likelihood of averting strokes and complete recovery compared with standard hospital emergency care, according to researchers at Weill Cornell Medicine, NewYork-Presbyterian, UTHealth Houston, Memorial Hermann-Texas Medical Center and five other medical centers across the United States.